IMNM vs REGN
IMNM: Immunome is a clinical-stage biotechnology company leveraging a proprietary platform to discover and develop novel, targeted oncology therapeutics. REGN: Regeneron is a leading biotechnology firm that leverages its human genetics research and proprietary technology to discover and commercialize innovative therapies for serious diseases.
Side-by-side fundamentals
| Metric | IMNM | REGN | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $28.52 | $834.04 | |
| Market cap as of 2026-08-24 | $3.2B | $78.4B | |
| P/E as of 2026-08-24 | n/a | 18.98 | |
| PEG as of 2026-08-24 | n/a | 1.08 | |
| Net margin as of 2026-08-24 | -1687.1% | +27.9% | REGN higher |
| Gross margin as of 2026-08-24 | n/a | +86.0% | |
| Operating margin as of 2026-08-24 | -1784.1% | +24.7% | REGN higher |
| ROE as of 2026-08-24 | -51.1% | +13.8% | REGN higher |
| ROA as of 2026-08-24 | -47.3% | +10.6% | REGN higher |
| Debt / equity as of 2026-08-24 | 0.00 | 0.09 | IMNM lower |
| Revenue growth (YoY) as of 2026-08-24 | -63.3% | +9.3% | REGN higher |
| Revenue CAGR (3y) SEC XBRL | -29.6% | +5.6% | REGN higher |
| Dividend yield as of 2026-08-24 | n/a | +0.5% | |
| Beta as of 2026-08-24 | 2.54 | 0.15 | |
| 1-year return as of 2026-08-21 close | +186.6% | +39.4% | IMNM higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.